KIGALI, July 14, 2025 – The World Health Organization today recommended the use of injectable lenacapavir (administered twice yearly) as an additional pre‑exposure prophylaxis option for HIV prevention. Announced at the International AIDS Society Conference in Kigali, Rwanda, the decision marks a turning point in HIV prevention strategy. Lenacapavir, a long‑acting capsid inhibitor branded as […]
WASHINGTON, June 23, 2025 – The U.S. Food and Drug Administration has approved lenacapavir as the world’s first twice-yearly injectable for HIV prevention—a landmark moment in the fight against one of the globe’s most enduring public health challenges. The drug, developed as a form of pre-exposure prophylaxis (PrEP), requires just two injections a year and […]
